BioSenic SA Logo

BioSenic SA

Developing ATO and cell therapies for autoimmune diseases and tissue regeneration.

BIOS | BR

Overview

Corporate Details

ISIN(s):
BE0970179827 (+1 more)
LEI:
549300HFIIMTOP1DFR76
Country:
Belgium
Address:
RUE GRANBONPRÉ 11, 1435 MONT-ST-GUIBERT
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

BioSenic SA is a biotechnology company focused on developing innovative clinical-stage therapies for autoimmune diseases and regenerative medicine. The company's pipeline is centered on two main platforms: a novel treatment using arsenic trioxide (ATO) to target the underlying causes of autoimmune and inflammatory conditions, and an allogeneic cell therapy platform aimed at tissue repair and organ regeneration. Formerly known as Bone Therapeutics, BioSenic combines its expertise in immunomodulation and cell therapy to address significant unmet medical needs.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for BioSenic SA and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-29 18:00
ISS
BIOS_PR_EN_2025 08_29.pdf
French 213.4 KB
2025-07-01 19:30
Capital/Financing Update
BIOS_PR_20250701_EN_final.pdf
English 346.5 KB
2025-07-01 19:30
M&A Activity
BIOS_PR_20250701_FR_final.pdf
French 342.1 KB
2025-06-10 07:30
Legal Proceedings Report
BIOS_PR_20250610_EN.pdf
English 329.1 KB
2025-06-10 07:30
Capital/Financing Update
BIOS_PR_20250610-FR.pdf
French 280.9 KB
2025-06-09 07:30
Capital/Financing Update
BIOS_PR_20250610_EN.pdf
English 329.1 KB
2025-06-09 07:30
Legal Proceedings Report
BIOS_PR_20250610-FR.pdf
French 280.9 KB
2025-05-08 18:30
Declaration of Voting Results & Voting Rights Announcements
BIOS_PR_2025_April_Denominator_EN.pdf
English 285.6 KB
2025-05-08 18:30
Declaration of Voting Results & Voting Rights Announcements
BIOS_PR_2025_avril_Denominator_FR.pdf
French 248.1 KB
2025-04-27 00:00
Report Publication Announcement
BIOS_PR_20250424_closing annual accounts_EN.pdf
English 224.0 KB
2025-04-27 00:00
Report Publication Announcement
BIOS_PR_20250424-comptes annuels_FR.pdf
French 236.5 KB
2025-04-10 18:00
Major Shareholding Notification
BIOS_PR_10042025- Notification_ABO_EN.pdf
English 268.1 KB
2025-04-10 18:00
Major Shareholding Notification
BIOS_PR_10042025-Notification_ABO_FR.pdf
French 300.6 KB
2025-04-07 20:30
Capital/Financing Update
BIOS_PR_20250407_EN.pdf
English 285.2 KB
2025-04-07 20:30
Capital/Financing Update
BIOS_PR_20250407_FR.pdf
French 245.9 KB

Automate Your Workflow. Get a real-time feed of all BioSenic SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for BioSenic SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-16 Rieger Francois Board Sell 2,500,000 25,000.00 EUR
2024-08-06 Rieger Francois Board Sell 868,653 7,186.87 EUR
2024-08-05 POMI SCHNEITER VERONIQUE Board Sell 534,750 4,331.47 EUR
2024-08-02 POMI SCHNEITER VERONIQUE Board Sell 193,900 1,609.37 EUR
2024-08-01 Rieger Francois Board Sell 1,236,684 11,463.87 EUR
2024-08-01 POMI SCHNEITER VERONIQUE Board Sell 140,003 1,246.03 EUR
2024-07-31 POMI SCHNEITER VERONIQUE Board Sell 503,771 4,685.07 EUR
2024-07-30 POMI SCHNEITER VERONIQUE Board Sell 360,021 3,348.20 EUR
2024-07-29 POMI SCHNEITER VERONIQUE Board Sell 372,893 3,430.62 EUR
2024-07-24 POMI SCHNEITER VERONIQUE Board Sell 2,168,361 21,033.10 EUR

Peer Companies

Company Country Ticker View
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan 9227
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan 3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan 4883
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden MODTX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland MOC
Mural Oncology PLC Logo
Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.
N/A
NANO MRNA Co.,Ltd. Logo
Biotech IP generator developing and licensing mRNA therapeutics using proprietary delivery systems.
Japan 4571
A marketing support firm using a vast consumer panel for data-driven research and PR campaigns.
Japan 4196
Neovacs Logo
Develops immunotherapy vaccines for autoimmune diseases & invests in BioTech/MedTech companies.
France ALNEV
Mineral explorer of rare earths, niobium, uranium, and copper assets in Australia and Zambia.
Australia N/A

Talk to a Data Expert

Have a question? We'll get back to you promptly.